Long-Term Safety and Clinical Outcomes of Motugivatrep (SJP-0132) 0.3% Ophthalmic Suspension in Patients with Dry Eye Disease: An Open-Label, Phase 3 Study.
Hori Y, Wada T, Omatsu K, SJP-0132 study group, SJP-0132 study group, SJP-0132 study group
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.